Recent News

Upcoming Seminars and Events

View upcoming seminars and events.

Learn more
559 News Items found
Man and woman in white lab coats looking at test tubes
In the Clinic
Single-Cell Analysis Enables Researchers to Understand the Differences within Tumors

Scientists are decoding the genetic changes that drive individual cancer cells. This may help them develop more-effective targeted therapies.
Jedd Wolchok and Charlotte Ariyan in the lab
In the Clinic
Chemotherapy-Immunotherapy Combination Aims to Knock Out Melanoma with a One-Two Punch

A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.
Medical oncologist Jae Park
In the Clinic
Longest-Running CAR T Trial Shows Which Patients Benefit Most, Have Fewest Side Effects

The study represents 20 years of research at MSK.
New Study Examines the Longest-Running CAR T Cell Trial and Finds Acute Lymphoblastic Leukemia Patients May Do Better When Treated Early

Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the treatment. Compared with patients with a greater amount of disease, those in the low-disease category lived significantly longer and experienced fewer life-threatening side effects.  
abstract red and blue lines suggestive of metabolic pathways
In the Lab
Scientists Create First-of-Its-Kind Metabolic Road Map of Cancer

The online resource will serve as a benchmark for researchers studying metabolism and cancer.
Proof of Principle: Tri-Institutional Therapeutics Discovery Institute Drug Candidates “Graduate” to Next Phase of Development

Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.
A gray blob marked RAS linked to colorful rods marked ICMT
In the Lab
Deciphering How Membrane Enzymes Work, with a Little Help from Beetles

The atomic structure of an elusive type of membrane protein has finally been solved by scientists at the Sloan Kettering Institute.
Illustration of cells with blue nuclei that have green DNA bits floating in the cytoplasm
In the Lab
Escape Artists: Cancer Cells Mimic Immune Cell Activity to Spread

Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.
Three-dimensional reconstruction of the blood vessels in a mouse thymus using light-sheet fluorescent microscopy
In the Lab
New Hope for Repairing a Damaged or Aging Immune System

Scientists have uncovered a molecule that, in mice, can promote the regeneration of the thymus, where T cells develop.
MP1104 binding to the kappa opioid receptor
Q&A
Building a Safer Opioid: MSK Research Seeks to Develop New Ways to Relieve Pain

Science could lead to a new type of opioid drug that blocks pain but has a lower potential for addiction or abuse.